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Evaluation of an inspiratory muscle trainer
in healthy humans
N. HART*, K. SYLVESTER*, S. WARD*, D. CRAMER*, J. MOXHAM{ AND M. I. POLKEY*
Respiratory Muscle Laboratories, *Royal Brompton and {Kings College Hospitals, London, U.K.
The Powerbreathe1 is an inspiratory muscle trainer promoted as improving inspiratory muscle strength (and
consequently exercise performance) in athletes and patients with respiratory disease. No published evidence
supports its ecacy. We performed a prospective randomized controlled study in which 12 normal subjects received
either Powerbreathe1 training or sham training for a 6-week period. The primary outcome measure was diaphragm
strength evaluated as twitch transdiaphragmatic pressure (Tw Pdi) but secondary outcome measures were provided
by full respiratory muscle assessment and cardiopulmonary exercise testing. An advantage to training was observed
when outcome was assessed by maximal static inspiratory mouth pressure (mean advantage 14?5 cm H2O, 95% CI
2?2–26?9 cm H2O, P0?025). However, no significant difference was observed between the groups in any other
parameter. In particular the DTw Pdi was not different between groups (mean ‘advantage’70?7 cmH2O, 95% CI–
7?0–5?5 cmH2O, P0?8). The continued sale and use of the Powerbreathe1 device is not justified by our data. A
sample size calculation showed that 234 subjects would need to be randomized to definitively refute the hypothesis
that Powerbreathe1 improves Tw Pdi and we argue that such a study is required.
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It has been claimed that inspiratory muscle training is of
benefit in patients with chronic obstructive pulmonary
disease (1) and in patients with respiratory muscle weakness
(2). The Powerbreathe1 is a threshold inspiratory muscle
training device sold direct to the public which is claimed to
improve inspiratory muscle strength and exercise perfor-
mance in both athletes and patients with respiratory disease
after 6 weeks of use. The device originated from the U.K.
but can be bought from the internet world-wide. The cost of
the device is currently US$80 and, at least in the U.K., is
not reimbursed to patients. For many patients this
represents a more than trivial investment yet no data exists
to support its ecacy.
The hypothesis that strengthening the inspiratory mus-
cles, by training, results in improved exercise performance
(or reduced dyspnoea at a given level of exerciseReceived 6 November 2000 and accepted in revised form 28
February 2001.
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0954-6111/01/060526+06 $35?00/0performance) is not new (3). Nevertheless, until recently it
has not been possible to test this hypothesis because the
methods commonly used to assess respiratory muscle
strength did not distinguish between a true increase in
strength and an improvement in the subject’s ability to
perform the test. However, diaphragm strength can now be
measured in an effort-independent fashion using the twitch
transdiaphragmatic pressure, Tw Pdi, elicited by bilateral
supramaximal anterior magnetic stimulation of the phrenic
nerves, BAMPS (4).
We therefore conducted a prospective randomized con-
trolled study of the Powerbreathe1 in which the primary
outcome measure was Tw Pdi. Subjects also underwent full
respiratory muscle studies, lung function tests and cardio-
pulmonary exercise testing.
Materials and methods
The protocol was approved by our ethics committee and all
subjects gave their informed consent to participate. Twelve
subjects [nine men and three women; mean (SD) age 32 (4?8)
years] were studied; all were free from respiratory or
neurological disease. All participants were highly motivated
and members of the pulmonary function or respiratory
muscle laboratories.# 2001 HARCOURT PUBLISHERS LTD
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Subjects were randomized to receive either active treatment
with Powerbreathe1 or sham therapy. The Powerbreathe1
is essentially a valve which only allows inspiratory airflow
once a threshold negative pressure is generated at the
mouth. Once the valve has opened the resistance to
inspiratory airflow is minimal.
The treatment group used the device in accordance with
the manufacturers instructions; in brief this entailed
performing 30 rapid inspirations from residual volume
(RV) to total lung capacity (TLC) twice daily. The opening
threshold of the device is adjusted by the trainee so that the
trainee can only just complete 30 inspirations. With
continued training the trainee finds it easier to reach the
threshold and the opening pressure is then made more
negative by adjustment of a screw controlling the valve.
Thus, the opening pressure after 6 weeks training was more
negative than at the start. The sham-training group were
given Powerbreathe1 trainers set at a minimal opening
pressure threshold and instructed not to increase this, but
their regime was otherwise identical. The compliance of the
subjects with training was monitored with the use of a diary
card.
MEASUREMENTS
Measurements were made before and after a 6-week period
of either real or sham training. The oesophageal pressure
required to open the valve used by each individual for
training was measured at the second assessment.
Lung function was assessed according to the guidelines of
the British Thoracic Society (5) using spirometry, whole
body plethysmography and 12-sec maximal voluntary
ventilation (Jaeger, Wurzburg, Germany).
An incremental cardiopulmonary exercise test to exhaus-
tion on a treadmill was performed using the Bruce protocol.
During this test we obtained breath by breath measure-
ments of ventilation, tidal volume, respiratory frequency,
oxygen uptake and carbon dioxide production (Jaeger).
Inspiratory muscle strength was measured using the
traditional method, mouth pressure during a maximal static
inspiratory effort (PImax), according to the method of Black
and Hyatt (6), modified by the use of a flanged mouthpiece.
The oesophageal pressure during this maximal effort
(Poesmax) was also recorded. The pressure at the mouth
was measured via a thin bore tube connected to a side
aperture on the mouthpiece and linked to the recording
system (see below).
Inspiratory muscle strength was also assessed using more
elaborate laboratory tests. Details may be found elsewhere
(7,8), but in essence we measured inspiratory muscle
strength as oesophageal (9) and transdiaphragmatic (10)
pressure during a maximal voluntary sniff (Sn Poes and Sn
Pdi) as well as the unpotentiated supramaximal twitch Tw
Pdi during BAMPS (4) using two 45-mm double-circular
coils each powered by a Magstim 200 stimulator (The
Magstim Co, Dyfed, U.K.) operating at 100% of maximal
output. To make these measurements oesophageal pressure(Poes) was measured using a 10 cm latex balloon attached
to a 110 cm PTFE coated catheter and inflated with 0?5ml
air. Gastric pressure (Pga) was measured using a similar
balloon catheter inflated with 2ml air. The two balloon
catheters were introduced pernasally and positioned in the
oesophagus and stomach in the conventional manner. The
catheters were connected to Validyne transducers (+200 cm
H2O, Validyne Corp., Northridge, CA, U.S.A.). Electrical
signals were amplified (Validyne Corp.) and passed via an
analogue to digital converter (NB-MIO-16, National
Instruments, Austin, Texas, U.S.A.) to an Apple Macintosh
computer running LabViewTM software (National Instru-
ments) and sampling at 100Hz.
ANALYSIS
Since a sham-training group was used the primary
comparison was made between changes before and after
training (or sham-training) in the two groups. Unpaired t-
tests (Statview 4?0, Abacus concepts, Berkeley, CA, U.S.A.)
were used for this purpose. For within-group before–after
comparisons the Wilcoxon signed rank test was used. In
both cases a level of P50?05 was taken as significant.
Results
All participants completed the trial. As judged by diary
cards, no subject omitted more than 5% of training
sessions. The mean (SD) opening pressure at the conclusion
of training in the intervention group was 132 (22) cmH2O,
or 82?6 (12?3)% of the oesophageal pressure observed
during a maximal effort (Poesmax). For the sham group the
mean (SD) opening pressure at the conclusion of training
was 37 (13) cmH2O, or 31?3 (12?1)% of Poesmax. Thus, the
training group had a load which was a mean 95 cm H2O
[95% confidence interval (CI) 72–117 cmH2O, P50?0001]
greater than the sham-training group or, expressed as %
Poesmax, which was 51?3% of Poesmax (95% CI 37–67% of
Poesmax, P50?0001) greater than the sham-training group.
There was no significant increase in lung function
parameters (of note vital capacity, total lung capacity or
peak inspiratory flow rate) in either the sham-training or
the training group, nor were the differences between groups
significant.
Strength data are shown in Table 1. At baseline
inspiratory muscle strength was not significantly different
between subjects allocated to training and those serving as
controls except as judged by Sn Poes (mean difference
21 cmH2O, 95% CI 2–70 cmH2O, P0?03). This difference
is not unexpected since Sn Poes is recognized to be lower in
women (9) and three of six controls were women. After
training the mean observed increases in PImax, Sn Poes, Sn
Pdi and Tw Pdi were 12?2%, 9?8%, 7?7% and 3?8%,
respectively. The corresponding figures for the sham-
training group were 1%, 6?5%, 2?5% and 6?8%; these
data are tabulated with confidence intervals in Table 2.
Comparing the two groups for change in these parameters
it is of note that we found a significant increase in PImax in
the training group (mean advantage with training
TABLE 1. Strength data
Tw Pdi (cmH2O) PImax (cmH2O)
Subject No. Group allocation Gender Before After Before After
1 Training Male 26?9 25?6 132 130
2 Training Male 24?1 27?7 128 140
3 Training Male 22?1 28?3 80 88
4 Training Male 39?4 39?0 149 173
5 Training Male 38?5 36?6 129 157
6 Training Male 19?3 19?5 149 172
7 Sham Female 29?5 25?7 89 95
8 Sham Male 23?9 21?2 90 99
9 Sham Female 24?5 22?2 104 98
10 Sham Male 30?2 42?5 126 117
11 Sham Male 27?3 30?3 127 132
12 Sham Female 23?5 27?8 119 121
TABLE 2. Strength data (with 95% confidence intervals) for training and control groups
Training group Control group Comparison of change in training
vs. control group
Test Mean value
pre-training
Mean value
post-training
Mean
change
Mean value
pre-training
Mean value
post-training
Mean
change
Mean
diff
P-value Lower
95%
CI
Upper
95%
CI
PImax
(cmH2O)
127?8 143?4 15?6 109?3 110?4 1?1 14?5 0?025 2?2 26?9
Sn Poes
(cmH2O)
134?7 147?9 13?2 98?8 105?2 6?4 6?8 0?300 77?1 20?8
Sn Pdi
(cmH2O)
141?4 152?3 10?9 120?2 123?3 3?1 7?8 0?365 710?7 26?4
Tw Pdi
(cmH2O)
28?4 29?5 1?1 26?5 28?3 1?8 70?7 0?800 77 5?5
528 N. HART ET AL.14?5 cmH2O, 95% CI 2?2–26?9 cmH2O, P0?025) whereas
other tests, and in particular the DTw Pdi, was not different
between groups (mean ‘advantage’ with training
70?7 cmH2O, 95% CI 77?0–5?5 cmH2O, P0?8).
Performance data are shown with confidence intervals
in Table 3. No significant improvement was observed in
either exercise duration, intensity or maximal voluntary
ventilation.
Discussion
Our data show that PImax increased in the training group,
but this was not confirmed by detailed tests to represent a
genuine increase in respiratory muscle strength and there
was no improvement in exercise performance. Since the
PImax maneuvre has many similarities with the training
maneuvre we suggest that this result represents a learningeffect; thus we reject the concept that use, by healthy
subjects, of the Powerbreathe1 device is beneficial.
Although this study is limited by its small sample size (see
below), we know of no data in the literature that do support
its use. Chest physicians should not advise purchase of the
Powerbreathe1 unless further data become available.
CRITIQUE OF THE METHOD
In the current study the subjects were well motivated and
demonstrated their adherence to the programme with diary
cards. At the completion of the study there was a clear
difference in the training load of the two groups. Therefore
three possible reasons exist why our study failed to show a
benefit with Powerbreathe1. First, there could be a genuine
benefit which our study failed to detect because the sample
size was too small. Second, although inspiratory muscle
TABLE 3. Exercise data (with 95% confidence intervals) for training and control groups
Training group Control group Comparison of change in training vs. control
group
Test Mean value
pretraining
Mean value
post-training
Mean
change
Mean value
pretraining
Mean value
post-training
Mean
change
Mean
diff
P-value Lower
95% CI
Upper
95% CI
MVV (lmin71) 174 186 12 151 158 6 5 0?659 721 32
Exercise time (sec) 848 887 39 750 754 4 35 0?229 726 95
Max min ventilation (lmin71) 122 113 79 105 101 74 75 0?711 727 19
Max HR (cmin71) 182 184 2 185 185 0 2 0?534 712 22
VO2max (mlmin
71 kg71) 44 40 75 39 39 0 74 0?140 710 2
VCO2 (lmin
71) 4?9 4?1 70?8 4?4 4?1 70?3 70?5 0?216 71?4 0?4
RQ (end-exercise) 1?30 1?28 70?02 1?30 1?28 70?02 0?00 0?411 0?28 0?13
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530 N. HART ET AL.training may be beneficial the Powerbreathe1 training
regime may not load the muscles suciently to train the
inspiratory muscles or, thirdly, inspiratory muscle training
may not be of value in healthy humans.
Clearly, if our sample size were too small we could have
missed a treatment effect. The use of parametric statistics
and confidence intervals allows an estimation of the
magnitude of difference we could have missed. Tables 2
and 3 show that we could have failed to detect an increase
in inspiratory muscle strength of approximately 20% and
an increase in exercise duration or peak ventilation of
approximately 10%. Although these might seem substantial
margins, it is important to recall that enthusiasts consider
that inspiratory muscle training can generate bigger
improvements; for example in the now classic paper by
Leith and Bradley strength training was reported to
increase inspiratory muscle strength, judged from a
maximal static effort, by 55% (3).
The sample size required to demonstrate a benefit is of
interest. All outcome measures used in previous studies
depend on patient effort or aptitude at performing the test.
This is particularly true of the PImax which, because it has
marked similarities to the training manoeuvre itself, may
increase simply because the subjects are better at perform-
ing the manoeuvre. It is therefore of interest that the DPImax
was significantly greater in the present study in the training
group. We suggest that this represents a ‘learning’ effect
which is unrelated to the contractile properties of the
inspiratory muscles. Nevertheless it may offer an explana-
tion for apparently positive results produced by inspiratory
muscle training previously.
Because we were concerned that PImax was not an
adequate test to evaluate the effects of Powerbreathe we
determined prior to the study that our primary aim would
be to evaluate inspiratory muscle training using a non-
volitional technique. We performed a sample size calcula-
tion using data from the control subjects with the premise
that a 10% increase in Tw Pdi would be clinically
worthwhile, and sought 80% power and a significance level
of P50?05. This calculation showed that 117 subjects
would be required in each group. Since the resources are
not currently available to our laboratory to randomize and
follow 234 subjects we opted to submit the present data for
publication, since we believed them to be hypothesis-
generating.
The remaining possibilities (that the Powerbreathe1
regime is insuciently rigorous to induce training or that
inspiratory muscle training itself can not occur in normal
subjects) are not distinguished by the current data.
However the pressures generated in the training group
were close to maximal and thus if the Powerbreathe1 is
insuciently rigorous this must be because the quantity of
training is insucient rather than the intensity. We know of
no data where phrenic nerve stimulation data has been used
to test either of these hypotheses specifically.
An additional limitation of the current study is that the
Powerbreathe1 was assessed in healthy volunteers. To
some extent this limits the extrapolation of our data, but it
should be recalled that the Powerbreathe1 is considered by
its manufacturer to be equally ecacious in healthy subjectsand patients with respiratory disease and to have the same
mode of action.
SIGNIFICANCE OF THE FINDINGS
The use of Powerbreathe1 has been justified almost entirely
by publications in abstract form only. Indeed a Medline
search performed using both the inventors name and the
term ‘Powerbreathe1’ failed to yield a single study
evaluating its ecacy. Despite this the device has been
favourably portrayed in the print and television media, and
indeed was exhibited in the Millennium Dome in London as
an achievement of British science. The device has also been
awarded a SMART Foresight award from the U.K.
government in recognition of ‘exceptional vision in devel-
oping new technologies’. Our data raise the serious
possibility that the device is of no value in increasing
inspiratory muscle strength or exercise performance and we
suggest that its current popularity is not justified by
scientific data. It is therefore a matter of concern that the
device is sold direct to the public without any form of
regulation.
The Powerbreathe1 is simply one example of an
inspiratory muscle training device; and strictly speaking,
our conclusions cannot be extended to other training
regimens. Nevertheless it is of interest that a meta-analysis
of training regimes in chronic obstructive pulmonary
disease (COPD) (11) concluded that the data provided
little support for this treatment while, more recently, a
controlled randomized study of 30 patients with COPD
failed to find an increase in maximal inspiratory pressure in
patients with COPD (1). Conversely, PImax can rise by up to
20% in patients treated only with placebo (12), presumably
as a result of a learning effect.
Magnetic stimulation of the phrenic nerves is a relatively
new technique which is acceptable both to normal subjects
and patients with respiratory disease (13, 14). Magnetic
stimulation has been shown to be suciently sensitive to
track the changes induced by low frequency fatigue in man
(13), and is especially advantageous for ‘within-occasion’
data (15). The principle advantage of using the Tw Pdi
elicited by magnetic stimulation is that the data are entirely
independent of the patients aptitude or motivation. This is
particularly relevant where the test manouvre closely
resembles the training manouvre. To our knowledge, no
previous study has evaluated an inspiratory muscle training
protocol using data obtained by phrenic nerve stimulation
as an endpoint. The disadvantage of using Tw Pdi is that,
because the twitch is usually about 20% of the value of the
voluntary manouvre (16), the between-occasion variability
is, as a proportion bigger than would be obtained with the
sniff manouvre; this variation is present irrespective of
stimulation modality (17). Thus to exclude change large
sample sizes may be required and we argue that such a
study is now warranted.
In conclusion our data provide no evidence base for the
current use of the Powerbreathe1 device. We suggest that a
randomized controlled study of sucient power be
performed to evaluate its position more precisely.
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